The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Chemotherapy for Neuroblastoma Market Research Report 2024

Global Chemotherapy for Neuroblastoma Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1743060

No of Pages : 92

Ask Your Query

Synopsis
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

Global Chemotherapy for Neuroblastoma market is projected to reach US$ 167.6 million in 2029, increasing from US$ 123 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chemotherapy for Neuroblastoma market research.

Key companies engaged in the Chemotherapy for Neuroblastoma industry include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Chemotherapy for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Chemotherapy for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Chemotherapy for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Baxter Healthcare
  • Ingenus Pharmaceuticals
  • ANI Pharmaceuticals
  • Teva Pharmaceuticals
  • Qilu Pharmaceutical
  • Pfizer
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Accord Healthcare
  • Viatris

Segment by Type

  • Cyclophosphamide
  • Cisplatin or Carboplatin
  • Vincristine
  • Doxorubicin (Adriamycin)
  • Etoposide
  • Other

Segment by Application

  • Hospital
  • Clinic
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Chemotherapy for Neuroblastoma report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

List of Tables
Table 1. Global Chemotherapy for Neuroblastoma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Cyclophosphamide
Table 3. Key Players of Cisplatin or Carboplatin
Table 4. Key Players of Vincristine
Table 5. Key Players of Doxorubicin (Adriamycin)
Table 6. Key Players of Etoposide
Table 7. Key Players of Other
Table 8. Global Chemotherapy for Neuroblastoma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Chemotherapy for Neuroblastoma Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Chemotherapy for Neuroblastoma Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Chemotherapy for Neuroblastoma Market Share by Region (2018-2023)
Table 12. Global Chemotherapy for Neuroblastoma Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 13. Global Chemotherapy for Neuroblastoma Market Share by Region (2024-2029)
Table 14. Chemotherapy for Neuroblastoma Market Trends
Table 15. Chemotherapy for Neuroblastoma Market Drivers
Table 16. Chemotherapy for Neuroblastoma Market Challenges
Table 17. Chemotherapy for Neuroblastoma Market Restraints
Table 18. Global Chemotherapy for Neuroblastoma Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Chemotherapy for Neuroblastoma Market Share by Players (2018-2023)
Table 20. Global Top Chemotherapy for Neuroblastoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy for Neuroblastoma as of 2022)
Table 21. Ranking of Global Top Chemotherapy for Neuroblastoma Companies by Revenue (US$ Million) in 2022
Table 22. Global 5 Largest Players Market Share by Chemotherapy for Neuroblastoma Revenue (CR5 and HHI) & (2018-2023)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Chemotherapy for Neuroblastoma Product Solution and Service
Table 25. Date of Enter into Chemotherapy for Neuroblastoma Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chemotherapy for Neuroblastoma Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Chemotherapy for Neuroblastoma Revenue Market Share by Type (2018-2023)
Table 29. Global Chemotherapy for Neuroblastoma Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 30. Global Chemotherapy for Neuroblastoma Revenue Market Share by Type (2024-2029)
Table 31. Global Chemotherapy for Neuroblastoma Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Chemotherapy for Neuroblastoma Revenue Market Share by Application (2018-2023)
Table 33. Global Chemotherapy for Neuroblastoma Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 34. Global Chemotherapy for Neuroblastoma Revenue Market Share by Application (2024-2029)
Table 35. North America Chemotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Chemotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Chemotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Chemotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. Europe Chemotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 40. Europe Chemotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 41. Asia-Pacific Chemotherapy for Neuroblastoma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 42. Asia-Pacific Chemotherapy for Neuroblastoma Market Size by Region (2018-2023) & (US$ Million)
Table 43. Asia-Pacific Chemotherapy for Neuroblastoma Market Size by Region (2024-2029) & (US$ Million)
Table 44. Latin America Chemotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Latin America Chemotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 46. Latin America Chemotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 47. Middle East & Africa Chemotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 48. Middle East & Africa Chemotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Chemotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 50. Baxter Healthcare Company Detail
Table 51. Baxter Healthcare Business Overview
Table 52. Baxter Healthcare Chemotherapy for Neuroblastoma Product
Table 53. Baxter Healthcare Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 54. Baxter Healthcare Recent Development
Table 55. Ingenus Pharmaceuticals Company Detail
Table 56. Ingenus Pharmaceuticals Business Overview
Table 57. Ingenus Pharmaceuticals Chemotherapy for Neuroblastoma Product
Table 58. Ingenus Pharmaceuticals Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 59. Ingenus Pharmaceuticals Recent Development
Table 60. ANI Pharmaceuticals Company Detail
Table 61. ANI Pharmaceuticals Business Overview
Table 62. ANI Pharmaceuticals Chemotherapy for Neuroblastoma Product
Table 63. ANI Pharmaceuticals Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 64. ANI Pharmaceuticals Recent Development
Table 65. Teva Pharmaceuticals Company Detail
Table 66. Teva Pharmaceuticals Business Overview
Table 67. Teva Pharmaceuticals Chemotherapy for Neuroblastoma Product
Table 68. Teva Pharmaceuticals Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 69. Teva Pharmaceuticals Recent Development
Table 70. Qilu Pharmaceutical Company Detail
Table 71. Qilu Pharmaceutical Business Overview
Table 72. Qilu Pharmaceutical Chemotherapy for Neuroblastoma Product
Table 73. Qilu Pharmaceutical Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 74. Qilu Pharmaceutical Recent Development
Table 75. Pfizer Company Detail
Table 76. Pfizer Business Overview
Table 77. Pfizer Chemotherapy for Neuroblastoma Product
Table 78. Pfizer Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 79. Pfizer Recent Development
Table 80. Hikma Pharmaceuticals Company Detail
Table 81. Hikma Pharmaceuticals Business Overview
Table 82. Hikma Pharmaceuticals Chemotherapy for Neuroblastoma Product
Table 83. Hikma Pharmaceuticals Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 84. Hikma Pharmaceuticals Recent Development
Table 85. Fresenius Kabi Company Detail
Table 86. Fresenius Kabi Business Overview
Table 87. Fresenius Kabi Chemotherapy for Neuroblastoma Product
Table 88. Fresenius Kabi Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 89. Fresenius Kabi Recent Development
Table 90. Accord Healthcare Company Detail
Table 91. Accord Healthcare Business Overview
Table 92. Accord Healthcare Chemotherapy for Neuroblastoma Product
Table 93. Accord Healthcare Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 94. Accord Healthcare Recent Development
Table 95. Viatris Company Detail
Table 96. Viatris Business Overview
Table 97. Viatris Chemotherapy for Neuroblastoma Product
Table 98. Viatris Revenue in Chemotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 99. Viatris Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chemotherapy for Neuroblastoma Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Chemotherapy for Neuroblastoma Market Share by Type: 2022 VS 2029
Figure 3. Cyclophosphamide Features
Figure 4. Cisplatin or Carboplatin Features
Figure 5. Vincristine Features
Figure 6. Doxorubicin (Adriamycin) Features
Figure 7. Etoposide Features
Figure 8. Other Features
Figure 9. Global Chemotherapy for Neuroblastoma Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 10. Global Chemotherapy for Neuroblastoma Market Share by Application: 2022 VS 2029
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Other Case Studies
Figure 14. Chemotherapy for Neuroblastoma Report Years Considered
Figure 15. Global Chemotherapy for Neuroblastoma Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Chemotherapy for Neuroblastoma Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Chemotherapy for Neuroblastoma Market Share by Region: 2022 VS 2029
Figure 18. Global Chemotherapy for Neuroblastoma Market Share by Players in 2022
Figure 19. Global Top Chemotherapy for Neuroblastoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy for Neuroblastoma as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Chemotherapy for Neuroblastoma Revenue in 2022
Figure 21. North America Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Chemotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 23. United States Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Chemotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 27. Germany Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Chemotherapy for Neuroblastoma Market Share by Region (2018-2029)
Figure 35. China Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Japan Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. South Korea Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Southeast Asia Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. India Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Australia Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Chemotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 43. Mexico Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Brazil Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Chemotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 47. Turkey Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Saudi Arabia Chemotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Baxter Healthcare Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 50. Ingenus Pharmaceuticals Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 51. ANI Pharmaceuticals Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 52. Teva Pharmaceuticals Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 53. Qilu Pharmaceutical Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 54. Pfizer Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 55. Hikma Pharmaceuticals Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 56. Fresenius Kabi Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 57. Accord Healthcare Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 58. Viatris Revenue Growth Rate in Chemotherapy for Neuroblastoma Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock